Explain this page
Arphra AIPlain-English read on ADMA Biologics, Inc.’s valuation06-10today
- ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline6h
- ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline6h
- DEADLINE ALERT for BTGO, VIA, Z, ADMA: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions7h
- DEADLINE ALERT for BTGO, VIA, Z, ADMA: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions7h
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$36.03
+320.44% vs spot
Recommendation
Strong Buy
15 of 16 methods
Method spread
10bull4bear
±5% threshold
Analyst PT consensus: $21.00 (+145.04%)
Candlestick · 1Y
Open in chart workstation →ADMA
8.31-52.51%H 18.00L 7.21MA50 10.36MA200 —Avg vol 5.5M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.13% | +0.71% | +4.00% | -40.15% | -56.89% | -53.02% | -52.04% | +120.88% | +419.39% | +21.39% | +0.23% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$8.57
35 sh
Bid
$8.25
10 sh
Ask
$8.70
50 sh
Spread
$0.450
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $139.16M | $49.38M | $0.20 |
| Q3 Sep 2025 | $134.22M | $36.43M | $0.15 |
| Q2 Jun 2025 | $121.98M | $34.22M | $0.14 |
| Q1 Mar 2025 | $114.8M | $26.9M | $0.11 |
| Q4 Dec 2024 | $117.55M | $111.9M | $0.46 |
| Q3 Sep 2024 | $119.84M | $35.91M | $0.15 |
Sector & industry today
LiveSectors
- Real Estate+1.28%
- Industrials+1.01%
- Basic Materials+0.65%
- Energy+0.59%
- Healthcare+0.03%
- Utilities-0.09%
- Financial Services-0.18%
- Communication Services-0.56%
- Technology-0.77%
- Consumer Cyclical-0.83%
- Consumer Defensive-0.98%
Top industries (issuer's industry highlighted)
- Biotechnology+7.27%
- Software - Services-5.92%
- Electronic Gaming & Multimedia-3.76%
- Financial - Mortgages-3.51%
- Software - Infrastructure-3.12%
- Electrical Equipment & Parts+2.70%
- Staffing & Employment Services-2.69%
- Apparel - Footwear & Accessories-2.61%
- Coal-2.36%
- Advertising Agencies+2.35%
- Engineering & Construction+2.33%
- Broadcasting-2.30%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadlinenewsfilecorp.com·Jun 22, 2026
- ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadlinenewsfilecorp.com·Jun 22, 2026
- DEADLINE ALERT for BTGO, VIA, Z, ADMA: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actionsglobenewswire.com·Jun 22, 2026
- DEADLINE ALERT for BTGO, VIA, Z, ADMA: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actionsglobenewswire.com·Jun 22, 2026
- ATTENTION ADMA INVESTORS: Contact Berger Montague About an ADMA Biologics, Inc. Class Action Lawsuitfeeds.newsfilecorp.com·Jun 22, 2026
- ATTENTION ADMA INVESTORS: Contact Berger Montague About an ADMA Biologics, Inc. Class Action Lawsuitfeeds.newsfilecorp.com·Jun 22, 2026
- Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harmnewsfilecorp.com·Jun 22, 2026
- Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harmnewsfilecorp.com·Jun 22, 2026
Recent analyst activity
DB- Jun 10, 2026PT$21.00Adma Biologics resumed with an Outperform at Raymond JamesRaymond James
- Jun 10, 2026GradeStrong Buy → OutperformRaymond James Starts ADMA Biologics (ADMA) at OutperformRaymond James
Peers
No peer list available for ADMA.
Total assets
$624.24M
Total debt
$79.89M
Cash & equiv
$87.63M
Operating CF
$50.4M
Free cash flow
$27.82M
Buybacks
-$31.94M
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $510.17M | $191.44M | $146.93M | $0.60 | +28.80% |
| FY 2024 | $426.45M | $138.98M | $197.67M | $0.81 | +46.35% |
| FY 2023 | $258.22M | $21.63M | -$28.24M | $-0.13 | -10.94% |
| FY 2022 | $154.08M | -$39.37M | -$65.9M | $-0.43 | -42.77% |
| FY 2021 | $80.94M | -$58.37M | -$71.65M | $-0.61 | -88.52% |